Establishing a Consistent Framework & Endpoints to Optimize Clinical Trial Design

Time: 11:20 am
day: Day One


  • Evaluate whether new therapeutics should be included or be tested side
    by side to approved inhibitors
  • Improve the predictability of endpoints from Phase I to Phase II, and Phase II to Phase III clinical trials
  • Map out the most promising surrogate endpoints and biomarkers that
    allow for earlier identification of drug efficacy